• More good news for LC ganetespib

    Asked by CAS1 on Monday, June 3, 2013

    More good news for LC ganetespib

    SPOTLIGHT ON... Synta surges on positive lung cancer data for ganetespib

    Shares of Synta ($SNTA) climbed more than 10% today after news spread that its drug ganetespib spurred a 32% increase in survival for advanced lung cancer patients. "The results presented today are exciting in indicating the potential for creating a new treatment option for patients with progressive disease and limited treatment options," said Dr. Philip Bonomi, Rush University Medical Center. "In addition, the results today provide convincing evidence for using rate of disease progression as a criterion for treatment selection. Similar criteria are increasingly common in other cancer types including breast, ovarian, and hematologic malignancies." Release

    0 Answers from the Community

    Help the community by answering this question:

    Create an account to post your answer Already have an account? Sign in!

    By using WhatNext, you agree to our User Agreement, and Privacy Policy

    Read and answer more lung cancer questions.  Also, don't forget to check out our Lung Cancer page.